Gossamer Bio Inc (GOSS) News & EventsGOSSGossamer Bio Inc

Gossamer Bio Enters $250M Private Placement Financing Agreement

Gossamer Bio entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing expected to provide aggregate gross proceeds of up to approximately $250M, before deducting placement agent fees and estimated offering expenses. The private placement consists of an initial closing, a committed second closing contingent upon FDA acceptance of the seralutinib new drug application in PAH and warrants exercisable upon FDA approval of seralutinib in PAH. The private placement includes $150M of committed capital, consisting of approximately $25M to be funded at the initial closing and an additional approximately $125M to be funded at a second closing upon FDA acceptance of the seralutinib NDA in PAH. The investors' obligations to fund the second closing remain subject to the NDA Acceptance Milestone occurring in 2026 and the satisfaction of other customary closing conditions. If the NDA Acceptance Milestone occurs in 2026, the Company expects to receive the full $150M of committed capital in 2026.The private placement includes participation from new and existing institutional investors, including EcoR1 Capital, 683 Capital Partners, LP, RA Capital Management, Coastlands Capital, Samsara BioCapital and Rock Springs Capital, among others. Leerink Partners and Cantor are acting as joint placement agents in connection with the private placement.

Gossamer Cash and Securities Total $57.0 Million

Cash, cash equivalents and marketable securities totaled $57.0 million as of June 30, 2026. Gossamer expects the combination of current cash, cash equivalents and marketable securities will be sufficient to fund its operating and capital expenditures into the first quarter of 2027. "We have worked hard to strengthen Gossamer and prepare the Company for what comes next," said Faheem Hasnain, Chairman, Co-Founder, and CEO of Gossamer. "We completed a productive Pre-NDA Type B meeting with the FDA, received the official minutes and remain on track to submit our NDA for seralutinib in PAH in September. We also reacquired worldwide rights to seralutinib and completed a convertible note exchange that substantially reduced our debt. We are in a better position today, and our focus remains on the work required to move seralutinib forward."

Stock Futures Surge as Oil Prices Plunge

Stock futures are sharply higher Monday as investors return from the weekend encouraged by easing geopolitical tensions and a steep decline in oil prices. Dow, S&P 500 and Nasdaq futures are all advancing ahead of the opening bell, with technology and travel stocks leading premarket gains as crude prices retreat.Markets are reacting positively to reports that the Trump administration has paused further military escalation with Iran to allow room for diplomatic efforts. The easing in tensions has sent Brent crude sharply lower, relieving concerns that higher energy prices could fuel inflation and complicate the Federal Reserve's policy outlook. Airline, cruise and other travel-related stocks are benefiting from the drop in oil, while energy shares are under pressure.Investor attention is focused on a week that includes the Federal Reserve's July policy meeting, second-quarter GDP data, the June personal consumption expenditures price index, and earnings from four of the "Magnificent Seven" companies. The combination of major economic data and heavyweight earnings is expected to drive market direction through the end of the week.Following last week's mixed market reaction to Alphabet and Tesla, results from Microsoft, Meta, Amazon and Apple are expected to provide the clearest indication yet of whether the AI-driven rally can regain momentum.In pre-market trading, S&P 500 futures rose 0.89%, Nasdaq futures rose 1.42% and Dow futures rose 1.15%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Forte Biosciencesup 40% after entering into a definitive agreement under which Argenxwill acquire the company for $77 per share in cashGossamer Bioup 28% after proceeding toward a planned NDA submission for seralutinib for the treatment of patients with PAH in September and reacquiring worldwide development and commercial rights to seralutinib from ChiesiD-Wave Quantumup 9% after AT&Tannounced an agreement to expand its use of D-Wave's quantum computing technology and plans to use the technology to address complex optimization challenges across its network operationsUP AFTER EARNINGS -Ensign Groupup 11%Baker Hughesup 3%AstraZenecaup 1%DOWN AFTER EARNINGS -Alpha Metallurgicaldown 4%Alliance Resource Partnersdown 1%LOWER -MapLight Therapeuticsdown 62% after reporting topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist co-formulated with a peripherally acting anticholinergic, in adults with an acute exacerbation of schizophreniaArgenxdown 1% after entering into an agreement to acquire Forte Biosciences for $77 per share in cash